Free Patient Event Nov. 7 Focuses on Navigating Through Breast Cancer
CINCINNATI—To educate on the latest breast cancer research from University of Cincinnati scientists as well as offer tips about risks, early detection and overcoming the disease, the UC Cancer Institute's Breast Cancer Center is hosting a free educational event for survivors, their families and the community.
The "Charting a Course: Breast Cancer Research, Risk Factors and Resilience" patient symposium, being held from 9 a.m. to 2 p.m. Saturday Nov. 7, at the Kingsgate Marriott Conference Center, 151 Goodman Drive, is free and open to the public. The event will involve presentations from experts about breast cancer risks, genetic testing, prevention and overall wellness, including nutrition, exercise, stress reduction and even humor.
"This is the third year for the event, which has been very successful in informing patients about the innovative research and treatments available at the UC Cancer Institute," says Elyse Lower, MD, director of the center, professor in the Division of Hematology Oncology at the UC College of Medicine and a UC Health oncologist. "This year, we decided to use a navigation theme, as cancer is truly a journey from diagnosis through survivorship, and it often involves many different aspects of treatment and research."
Tags
Related Stories
EveryDay Health: Ways to manage symptoms linked to multiple...
March 26, 2024
The University of Cincinnati's Ed Faber spoke with EveryDay Health about ways to manage symptoms of multiple myeloma including numbness, pain or tingling in your arms and legs.
Spectrum News: Ohio Voices comes to Cincinnati
March 26, 2024
Ohio Voices, a video segment produced by Spectrum News, paid a visit to the University of Cincinnati to lift the voices of students, staff and faculty. Nine Bearcats were featured in the recent segment.
Collaborative University of Cincinnati Cancer Center team opens...
March 26, 2024
A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, the most deadly form of brain tumors.